Jing Jin
Research Subjects
Jing Jin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bo Shen
Harmony Technology Co., Ltd., Beijing, China
1 shared publication - Chenxi Yu
Research Center of Big Data Technology Nanhu Laboratory,JiaXing,China
1 shared publication - Guihua Yang
Harmony Technology Co., Ltd., Beijing, China
1 shared publication - Haixia Yang
Harmony Technology Co., Ltd., Beijing, China
1 shared publication - Huijie Si
Harmony Technology Co., Ltd., Beijing, China
1 shared publication - Jiachen Lin
Department of Orthopedic Surgery, Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Transplantation of Human Umbilical Cord‐Derived Mesenchymal Stem Cells Improves Cartilage Repair in a Rabbit Model
The aim of this study was to investigate the therapeutic efficacy and safety of transplanting human umbilical cord blood‐derived mesenchymal stem cells (hUCB‐MSCs) in the treatment of cartilage injury. First, the articular cartilage defect model in rabbits was constructed. Then, the identified hUCB‐MSCs and rabbit bone marrow stem cells (rBM‐MSCs) were transplanted into the bone defect, respectively, and the cartilage repair effect was observed by hematoxylin‐eosin (HE) staining and immunohistochemistry. Besides, the glycosaminoglycan (GAG) content and biomechanics of the restoration area were also evaluated. In our study, hUCB‐MSCs and rBM‐MSCs exhibited typical MSC characteristics, with positive expressions of CD73, CD105, and CD90 and negative for CD45, CD34, CD14, and HLA‐DR. After the transplantation of hUCB‐MSCs and rBM‐MSCs, the overall quality of cartilage tissue was significantly improved, and the recipients did not show significant side effects in general. However, the expression of matrix metalloproteinase‐13 (MMP‐13) in the de novo tissues of the hUCB‐MSCs and rBM‐MSCs groups was both increased, indicating that the novel tissues may have some potential osteoarthritic changes. In conclusion, our results suggest the therapeutic effect of hUCB‐MSCs transplantation in cartilage regeneration, providing a promising future in the clinical treatment of cartilage injury.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessTransplantation of Human Umbilical Cord‐Derived Mesenchymal Stem Cells Improves Cartilage Repair in a Rabbit Model
The aim of this study was to investigate the therapeutic efficacy and safety of transplanting human umbilical cord blood‐derived mesenchymal stem cells (hUCB‐MSCs) in the treatment of cartilage injury. First, the articular cartilage defect model in rabbits was constructed. Then, the identified hUCB‐MSCs and rabbit bone marrow stem cells (rBM‐MSCs) were transplanted into the bone defect, respectively, and the cartilage repair effect was observed by hematoxylin‐eosin (HE) staining and immunohistochemistry. Besides, the glycosaminoglycan (GAG) content and biomechanics of the restoration area were also evaluated. In our study, hUCB‐MSCs and rBM‐MSCs exhibited typical MSC characteristics, with positive expressions of CD73, CD105, and CD90 and negative for CD45, CD34, CD14, and HLA‐DR. After the transplantation of hUCB‐MSCs and rBM‐MSCs, the overall quality of cartilage tissue was significantly improved, and the recipients did not show significant side effects in general. However, the expression of matrix metalloproteinase‐13 (MMP‐13) in the de novo tissues of the hUCB‐MSCs and rBM‐MSCs groups was both increased, indicating that the novel tissues may have some potential osteoarthritic changes. In conclusion, our results suggest the therapeutic effect of hUCB‐MSCs transplantation in cartilage regeneration, providing a promising future in the clinical treatment of cartilage injury.